Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02725515 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT02725515 is a Phase 2 study that has completed, run by Xencor. The registered enrollment target is 105 participants.
The verdict
NCT02725515, a Phase 2 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
Interventions
- BIOLOGICAL XmAb5871
- BIOLOGICAL Placebo to match XmAb5871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02725515
The ClinicalTrials.gov registry entry for NCT02725515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb5871 is the first listed.
NCT02725515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02725515 about?
NCT02725515 is a clinical study titled "A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus". The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
What is the current status of trial NCT02725515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2016-02-16. Estimated completion is 2018-07-17.
What interventions are being tested in trial NCT02725515?
The interventions under investigation include: XmAb5871 (BIOLOGICAL), Placebo to match XmAb5871 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02725515?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.